RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, and St. Jude Children’s Research Hospital today announced their recent publication, “Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination,” in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics.
RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, today announced a collaboration with St. Jude Children’s Research Hospital. RPRD Diagnostics will perform preemptive, comprehensive clinical pharmacogenetics testing for St. Jude’s PG4KDS program.
RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, today announced a strategic partnership with Orient Bio Inc., a leading South Korean biotechnology company.
RPRD Diagnostics announced a collaboration with Children’s Minnesota dedicated to implementing a pharmacogenomic testing process. … By implementing this process the aim is to ensure patients get the right medication at the right time, making care more precise and more affordable.
To meet the growing demand for preemptive pharmacogenomic risk factor screening that may one day aid drug prescription practices, Thermo Fisher Scientific today introduced PharmacoScan Solution, a new microarray-based research tool that contains pharmacogenomic content with relevant markers involved in absorption, distribution, metabolism and excretion (ADME) pathways of commonly prescribed medicines.
RPRD (Right Person Right Drug) Diagnostics today announced its founding as a spin-off from the Medical College of Wisconsin (MCW). As a precision medicine company, RPRD Diagnostics is focused on providing comprehensive pharmacogenetics testing services, which analyze patients’ genomes for variations that are known to impact drug safety and efficacy, in a CLIA-certified lab.